There is encouraging news in the fight against cancer.
Scientists are developing a record number of new medicines to treat the most prevalent and deadly forms of cancer.
Some 750 cancer-fighting medicines are now being tested in human clinical trials or await approval by the Food and Drug Administration, according to a new report released by the Pharmaceutical Research and Manufacturers of America.
Cancer remains the second-leading cause of death in America, after heart disease, and accounts for one of every four deaths. More than 1.4 million Americans will be diagnosed with cancer this year, according to the National Cancer Institute.
But each new treatment option provides another glimmer of hope in the fight against cancer.
“The 750 new medicines now in the development pipeline will add to the substantial progress that biopharmaceutical companies have made in the fight against cancer over the last five years,” said Billy Tauzin, PhRMA president and CEO.
The cancer medicines now being developed include 113 for lung cancer, the leading cause of cancer death in the U.S.; 90 for breast cancer, which is expected to strike more than 180,000 American women this year; 88 for prostate cancer, which this year is expected to kill 28,000 American men; and 65 for colorectal cancer, the third-most-common cancer among men and women.
Additional experimental cancer medicines target such diseases as brain, kidney, ovarian, pancreatic and skin cancers. For more information on new medicines being developed, visit www.phrma.org.